comparemela.com

Sanjayak Satapathy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Blood biomarkers in TGF-β pathway identify hidden liver cancer risk

A new research paper was published in Genes & Cancer on February 5, 2023, entitled, "Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis."

Blood Proteomic Markers Stratify HCC Risk in Cirrhosis Patients

Blood Proteomic Markers Stratify HCC Risk in Cirrhosis Patients
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Review focuses on the link between the pathogenesis and management of hepatocellular carcinoma

Genes Linked to Hepatocellular Carcinoma Treatment & Prevention

Genes Linked to Hepatocellular Carcinoma Treatment & Prevention
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

One-year kidney allograft outcomes do not differ by hepatitis C status of donor

 E-Mail IMAGE: Recipients of kidneys from donors infected with HCV have similar kidney allograft function and probability of rejection in the first year after transplantation compared to those who received kidneys from. view more  Credit: AJKD, 2020 Study published in the American Journal of Kidney Diseases (AJKD) shows that kidney allograft outcomes one year post-transplantation in hepatitis C virus (HCV)-negative recipients do not differ by the HCV status of the donor. Transplant centers are increasingly willing to transplant kidneys from hepatitis C (HCV)-infected donors to HCV-negative recipients. Data on the long-term outcomes following these recipients are sparse. The aim of this single-center, retrospective study was to compare 1-year kidney outcomes in HCV-negative transplant recipients who received an organ either from a donor with or without HCV infection. The 1-year post-transplant kidney outcomes (including allograft function, development of de novo dono

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.